HUMAN LEUKEMIC DIFFERENTIATION--ANTI-SENSE RNA STUDIES
HUMAN LEUKEMIC DIFFERENTIATION--ANTI-SENSE RNA STUDIES
批准号:
3458969
负责人:
Mark L Tykocinski
金额:
$9.43万
依托单位国家:
美国
项目类别:
财政年份:
1988
资助国家:
美国
项目状态:
已结题
起止时间:
1988-05-01 至 1993-04-30
关键词:
RNA biotechnology cell bank /registry cell differentiation colony stimulating factor complementary DNA cytogenetics flow cytometry gene expression genetic library genetic markers genetic promoter element genetic transcription hematopoiesis immunochemistry immunofluorescence technique leukemia messenger RNA molecular cloning molecular oncology mutant neoplasm /cancer genetics neoplastic cell neoplastic transformation nucleic acid probes plasmids protooncogene transfection transposon /insertion element
中文摘要
可诱导的人髓性白血病细胞系提供了实验性的
获得白血病细胞分化和正常
造血 有可能细胞分化策略
最终可以提供替代方案,
用于人类临床管理的细胞破坏
造血系统恶性肿瘤 反义RNA转染
分析提供了一种直接评估功能作用的方法,
某些基因,例如,原癌基因与集落刺激
因子(CSF)基因,在白血病分化程序。 最近
我们实验室的研究已经确立了高拷贝的效用
有效反义RNA的附加型复制子的数量-
人造血细胞中基因表达的介导抑制
细胞 建议的实验是针对:1)优化
基于附加型复制子的组成型和诱导型转基因
在人类造血细胞中的表达,2)研究
原癌基因和CSF mRNA表达在一组可诱导的
人髓性白血病细胞系(HL-60,ML-1,K562,KG-1,
U937),特别注意年表和血统
基因表达变化的特异性,3)反义RNA
突变分析,以确定哪些,如果有的话,表达
原癌基因和CSFs在白血病中起着必要的作用。
分化,和4)1,25-二羟维生素D3的衍生
(1,25(OH)2D 3)诱导特异性HL-60 cDNA,
差异筛选和克隆方法以及功能
通过反义RNA转染评估这些基因
实验 拟议的研究应有助于
了解正常和
白血病造血,并可以提供一般的见解,
反义RNA技术的有效利用,
特定基因在人类造血细胞功能中的作用,
分化
英文摘要
Inducible human myeloid leukemic cell lines provide experimental
access to events in both leukemic cell differentiation and normal
hematopoiesis. It is possible that cytodifferentiation strategies
could ultimately provide alternatives to ones based upon
cytodestruction for the clinical management of human
hematopoietic malignancies. Anti-sense RNA transfection
analysis offers a means for directly assessing the functional role
of certain genes, e.g., protooncogenes and colony stimulating
factor (CSF) genes, in leukemic differentiation programs. Recent
studies in our laboratory have established the utility of high copy
number episomal replicons for the effective anti-sense RNA-
mediated inhibition of gene expression in human hematopoietic
cells. The proposed experiments are directed at: 1) optimization
of episomal replicon-based constitutive and inducible transgene
expression in human hematopoietic cells, 2) investigation of
protooncogene and CSF mRNA expression in a panel of inducible
human myeloid leukemic cell lines (HL-60, ML-1, K562, KG-1,
U937), with specific attention to the chronology and lineage
specificity of changes in gene expression, 3) anti-sense RNA
mutational analysis to determine which, if any, expressed
protooncogenes and CSFs play an obligatory role in leukemic
differentiation, and 4) derivation of 1,25-dihydroxyvitamin D3
(1,25(OH)2D3) induction-specific HL-60 cDNAs through
differential screening and cloning methodologies and functional
evaluation of these genes through anti-sense RNA transfection
experiments. The proposed studies should contribute to an
understanding of the molecular mechanisms underlying normal and
leukemic hematopoiesis, and could provide general insights into
the effective use of anti-sense RNA technology in studying the
role of specific genes in human hematopoietic cell function and
differentiation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Placental Protein 14 as a Lectin-Like Immunomodulator
-
批准号:6581043
-
项目类别:
-
资助金额:$4.03万
-
财政年份:2002
-
负责人:Mark L Tykocinski
-
依托单位:
Placental Protein 14 as a Lectin-Like Immunomodulator
-
批准号:6690355
-
项目类别:
-
资助金额:$4.03万
-
财政年份:2002
-
负责人:Mark L Tykocinski
-
依托单位:
Placental Protein 14 as a Lectin-Like Immunomodulator
-
批准号:6826845
-
项目类别:
-
资助金额:$4.03万
-
财政年份:2002
-
负责人:Mark L Tykocinski
-
依托单位:
CORE--MOLECULAR BIOLOGY
-
批准号:6100504
-
项目类别:
-
资助金额:$4.59万
-
财政年份:1998
-
负责人:Mark L Tykocinski
-
依托单位:
CELLULAR CANCER VACCINES
-
批准号:7104290
-
项目类别:
-
资助金额:$34.44万
-
财政年份:1997
-
负责人:Mark L Tykocinski
-
依托单位:
CELLULAR CANCER VACCINES
-
批准号:6787689
-
项目类别:
-
资助金额:$35.27万
-
财政年份:1997
-
负责人:Mark L Tykocinski
-
依托单位:
CELLULAR CANCER VACCINES--GPI PROTEIN TRANSFER
-
批准号:2896054
-
项目类别:
-
资助金额:$25.95万
-
财政年份:1997
-
负责人:Mark L Tykocinski
-
依托单位:
CORE--MOLECULAR BIOLOGY
-
批准号:6235758
-
项目类别:
-
资助金额:$4.97万
-
财政年份:1997
-
负责人:Mark L Tykocinski
-
依托单位:
CELLULAR CANCER VACCINES--GPI PROTEIN TRANSFER
-
批准号:6376458
-
项目类别:
-
资助金额:$27.33万
-
财政年份:1997
-
负责人:Mark L Tykocinski
-
依托单位:
CELLULAR CANCER VACCINES--GPI PROTEIN TRANSFER
-
批准号:2372175
-
项目类别:
-
资助金额:$23.77万
-
财政年份:1997
-
负责人:Mark L Tykocinski
-
依托单位:
CELLULAR CANCER VACCINES
-
批准号:7236697
-
项目类别:
-
资助金额:$33.44万
-
财政年份:1997
-
负责人:Mark L Tykocinski
-
依托单位:
CELLULAR CANCER VACCINES--GPI PROTEIN TRANSFER
-
批准号:2748946
-
项目类别:
-
资助金额:$24.41万
-
财政年份:1997
-
负责人:Mark L Tykocinski
-
依托单位:
CELLULAR CANCER VACCINES
-
批准号:6929244
-
项目类别:
-
资助金额:$35.27万
-
财政年份:1997
-
负责人:Mark L Tykocinski
-
依托单位:
CELLULAR CANCER VACCINES--GPI PROTEIN TRANSFER
-
批准号:6173494
-
项目类别:
-
资助金额:$26.63万
-
财政年份:1997
-
负责人:Mark L Tykocinski
-
依托单位:
CELLULAR CANCER VACCINES
-
批准号:6685665
-
项目类别:
-
资助金额:$35.27万
-
财政年份:1997
-
负责人:Mark L Tykocinski
-
依托单位:
HEMATOPOIETIC PP14--AN ANTIINFLAMMATORY CYTOKINE
-
批准号:2330446
-
项目类别:
-
资助金额:$28.61万
-
财政年份:1996
-
负责人:Mark L Tykocinski
-
依托单位:
HEMATOPOIETIC PP14--AN ANTIINFLAMMATORY CYTOKINE
-
批准号:6149803
-
项目类别:
-
资助金额:$34.13万
-
财政年份:1996
-
负责人:Mark L Tykocinski
-
依托单位:
PLACENTAL PROTEIN 14 AS A UNIQUE IMMUNOREGULATOR
-
批准号:6285652
-
项目类别:
-
资助金额:$39.18万
-
财政年份:1996
-
负责人:Mark L Tykocinski
-
依托单位:
PLACENTAL PROTEIN 14 AS A UNIQUE IMMUNOREGULATOR
-
批准号:6627854
-
项目类别:
-
资助金额:$41.57万
-
财政年份:1996
-
负责人:Mark L Tykocinski
-
依托单位:
PLACENTAL PROTEIN 14 AS A UNIQUE IMMUNOREGULATOR
-
批准号:6698823
-
项目类别:
-
资助金额:$42.81万
-
财政年份:1996
-
负责人:Mark L Tykocinski
-
依托单位:
海外基金